Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 1
1978 1
1979 2
1980 2
1981 1
1982 1
1983 3
1984 7
1985 1
1986 7
1987 7
1988 6
1989 4
1990 10
1991 12
1992 18
1993 20
1994 18
1995 27
1996 20
1997 25
1998 22
1999 32
2000 32
2001 26
2002 42
2003 45
2004 42
2005 29
2006 35
2007 32
2008 35
2009 36
2010 30
2011 44
2012 48
2013 55
2014 60
2015 64
2016 67
2017 58
2018 58
2019 66
2020 55
2021 62
2022 71
2023 73
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

1,273 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Chronic Leukemia"
Page 1
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.
Vetrie D, Helgason GV, Copland M. Vetrie D, et al. Nat Rev Cancer. 2020 Mar;20(3):158-173. doi: 10.1038/s41568-019-0230-9. Epub 2020 Jan 6. Nat Rev Cancer. 2020. PMID: 31907378 Free article. Review.
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. ...In AML, LSCs can arise from multiple cell types through the activity of a …
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML …
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Winters AC, et al. Transplant Cell Ther. 2022 Oct;28(10):694.e1-694.e9. doi: 10.1016/j.jtct.2022.07.022. Epub 2022 Jul 25. Transplant Cell Ther. 2022. PMID: 35902048 Free article.
Relapse, transplantation-related mortality, incidence of acute and chronic graft-versus-host-disease (GVHD), and death from any cause were also recorded. ...Finally, although pre-SCT MRD by flow cytometry was significantly predictive of post-SCT relapse and survival …
Relapse, transplantation-related mortality, incidence of acute and chronic graft-versus-host-disease (GVHD), and death from any cause …
GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT.
Wang D, Sun Z, Zhu X, Zheng X, Zhou Y, Lu Y, Yan P, Wang H, Liu H, Jin J, Zhu H, Sun R, Wang Y, Fu B, Tian Z, Wei H. Wang D, et al. Blood. 2022 Dec 29;140(26):2788-2804. doi: 10.1182/blood.2022015474. Blood. 2022. PMID: 35981475 Free PMC article.
Relapse is a leading cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML). However, the underlying mechanisms remain poorly understood. Natural killer (NK) cells play a crucial role in tumor surveillance and c …
Relapse is a leading cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia ( …
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC. Woyach JA, et al. Cancer Discov. 2024 Jan 12;14(1):66-75. doi: 10.1158/2159-8290.CD-23-0670. Cancer Discov. 2024. PMID: 37930156 Clinical Trial.
We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma (NHL), or Waldenstrom macroglobulinemia (WM), re …
We evaluated the safety, pharmacology, and antitumor activity of nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight …
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.
Holtan SG, Savid-Frontera C, Walton K, Eaton AA, Demorest C, Hoeschen A, Zhang L, Reid K, Kurian T, Sayegh Z, Julia E, Maakaron J, Bachanova V, Jurdi NE, MacMillan ML, Weisdorf DJ, Felices M, Miller JS, Blazar BR, Davila ML, Betts BC. Holtan SG, et al. Clin Cancer Res. 2023 Mar 14;29(6):1114-1124. doi: 10.1158/1078-0432.CCR-22-2837. Clin Cancer Res. 2023. PMID: 36622700 Free PMC article.
CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic act …
CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed w …
Chronic lymphocytic leukemia treatment algorithm 2018.
Parikh SA. Parikh SA. Blood Cancer J. 2018 Oct 3;8(10):93. doi: 10.1038/s41408-018-0131-2. Blood Cancer J. 2018. PMID: 30283014 Free PMC article. Review.
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as ibrutinib, idelalisib, and venetoclax), and next-generation anti-CD20 monoclonal antibodies …
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of …
Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M. Wall M. Methods Mol Biol. 2017;1541:209-222. doi: 10.1007/978-1-4939-6703-2_18. Methods Mol Biol. 2017. PMID: 27910026 Review.
Cytogenetics forms the cornerstone of the most widely adopted prognostic scoring systems in MDS, the international prognostic scoring system (IPSS) and the revised international prognostic scoring system (IPPS-R). Cytogenetic parameters a …
Cytogenetics forms the cornerstone of the most widely adopted prognostic scoring systems in MDS, the international prognostic …
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S, Sutton LA, Ljungström V, Capasso A, Pandzic T, Weström S, Foroughi-Asl H, Skaftason A, Gellerbring A, Lyander A, Gandini F, Gaidano G, Trentin L, Bonello L, Reda G, Bödör C, Stavroyianni N, Tam CS, Marasca R, Forconi F, Panayiotidis P, Ringshausen I, Jaksic O, Frustaci AM, Iyengar S, Coscia M, Mulligan SP, Ysebaert L, Strugov V, Pavlovsky C, Walewska R, Österborg A, Cortese D, Ranghetti P, Baliakas P, Stamatopoulos K, Scarfò L, Rosenquist R, Ghia P. Bonfiglio S, et al. Blood Adv. 2023 Jun 27;7(12):2794-2806. doi: 10.1182/bloodadvances.2022008821. Blood Adv. 2023. PMID: 36696464 Free PMC article.
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. ...Using an extended capture-based panel, only BRAF and IKZF3 mutations showed a predominance in relapsing cases, who were enriched for del(8p) (n = 11; 3 BTKwt). Fin …
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. ...Using an extended captu …
Acute lymphoblastic leukemia.
Chan KW. Chan KW. Curr Probl Pediatr Adolesc Health Care. 2002 Feb;32(2):40-9. doi: 10.1067/mps.2002.121790. Curr Probl Pediatr Adolesc Health Care. 2002. PMID: 11951089 Review.
Acute leukemia is the most common childhood malignancy, representing 30% of all cancer in American children under the age of 15 years and 12% of cancer cases in those ages 15 to 19 years old. In the United States, approximately 2500 new cases are diagnosed annually; 80% of …
Acute leukemia is the most common childhood malignancy, representing 30% of all cancer in American children under the age of 15 years …
Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?
Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R. Baliakas P, et al. J Intern Med. 2016 Apr;279(4):347-57. doi: 10.1111/joim.12455. Epub 2015 Dec 28. J Intern Med. 2016. PMID: 26709197 Free article. Review.
The remarkable clinical heterogeneity in chronic lymphocytic leukaemia (CLL) has highlighted the need for prognostic and predictive algorithms that can be employed in clinical practice to assist patient management and therapy decisions. Over the last 20 years …
The remarkable clinical heterogeneity in chronic lymphocytic leukaemia (CLL) has highlighted the need for prognostic and pr …
1,273 results